Company
Business
Stem Cell Therapy
Organoid
CDMO Business
2025
12월한국파스퇴르 연구소와 모낭 오가노이드 스크리닝 공동 연구계약 체결
07월무릎 골관절염 치료제 융복합제제 기술로 미국 특허 등록
04월세계골관절염학회(OARSI)서 '오스카(OSCA)' 임상 1상 결과 발표
03월골관절염 치료제 '오스카(OSCA)' 첫 환자 투약으로 임상 2a상 개시
02월일본 후생노동성 지방 줄기세포 재생의료 최종 승인
2024
11월유영제약과 골관절염 치료제 '오스카(OSCA)' 라이선스 아웃 계약 체결
07월아토피 피부염 치료제 '퓨어스템-에이디 주' 임상 3상 톱라인 데이터 결과 발표
05월HLB바이오스텝과 오가노이드 기반 연구개발 MOU 체결
04월식품의약품안전체 아토피 피부염 치료제 '퓨어스템-에이디 주' 치료목적 사용 승인
01월GMP센터, 일본 후생노동성 특정세포가공물 제조 인정 승인
2023
11월면역조절능 특화 세포치료제 기술 중국 특허 등록
08월골관절염 치료제 '퓨어스템-오에이 키트 주' 첫 환자 투약으로 임상 1상 개시
05월국제정형외과학회(ATiO)서 골관절염 치료제 '퓨어스템-오에이 키트 주' 성과 발표
02월피앤케이피부임상연구센터와 피부 오가노이드 기반 효능평가플랫폼 개발 MOU 체결
2022
09월서울대 공동연구 세계 최초 '인체 피부와 모낭 완벽 구현한 피부오가노이드' 국제 학술저널 게재
07월줄기세포 기반 융복합제제 골관절염 치료제 유럽 특허 등록
05월강원대병원과 첨단재생의료 연구협력 MOU 체결
04월와이제이세라퓨틱스와 CDMO 계약 체결
2021
07Granted a license for the management of human cells etc.
05Approval of IND application for Phase 3 clinical trial of Furestem-AD inj by MFDS
04Entered into MOU with Seoul National University Bundang Hospital
02Acquisition of cosmetics business
2020
12Obtained a manufacturing license from MFDS for advanced biopharmaceuticals
04Signed MOU for gene and cell therapy research with G+FLAS Life Sciences
2019
03Signed exclusive rights for domestic sales of Furestem-AD and technology transfer agreement with HYUNDAI Bioland
2018
02Received IND approval for Phase 1/2a clinical trial of Furestem-RA from MFDS
2017
09Signed Joint Development Agreement with Germany’s Heraeus Medical GmbH for osteoarthritis stem cell therapy
2016
10Nominated for Korea-China Science Technology Collaboration Project – Researching stem cell therapy for neurological disorders targeted for Asians
10Nominated by The Ministry of Trade, Industry and Energy as a "K-BrainPower" company
02Signed stem cell conditioned media joint business contract with Dongwha Pharmaceutical (MOU)
2015
12Listed on KOSDAQ
08Concluded the contract of iNSC technology joint business with Orig3n of the U.S
08Expanded the Construction of Stem Cell GMP Center
08Selected for the business in the development of high tech medical technology – Phases 1/2a clinical research for Crohn’ disease
07Acquired ISO certificates (ISO 9001, ISO 14001)
06Selected for the future industry leading technology development business – R&D for cell culture system
01Concluded the joint business contract for the stem cell conditioned medium cosmetics with COSON.
2014
12Approved of Furestem-CD® Phase 1 (added psoriasis indicant)
12Concluded a contract for the stem cell therapy sales right and joint development with Daewoong Pharmaceutical Inc
09Selected for the high tech medical technology development business – Occlusive arteriopathy preclinical
06Certified for Technology INNO-BIZ
05Approved of Furestem-RA® Phase 1
2013
12Changed business name to Kangstem Biotech
10Selected for the parts material business – GvHD preclinical
06Approved of Furestem-CD® Phases 1 & 2a
01Approved of Furestem-AD® Phases 1 & 2a
2012
12Selected for the public health medical research development business - Psoriasis preclinical
05Selected for the public health medical study development business - Crohn’s disease preclinical
02Completed the construction of Stem Cell GMP Center
2011
12Selected for the industry & academy cooperative technology transfer business – Atopic Dermatitis preclinical
08Recognized for the company auxiliary research center by KOITA (Korea Industry & Technology Association)
02Certified for the venture company by KIBO (Korea Technology Finance Corporation)
2010
10Established Kangstem Holdings